{"transactions":[{"id":4095,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:21.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001454771-26-000002","document":"form4-09042026_060910.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454771/000145477126000002/form4-09042026_060910.xml","form_type":"4"}},{"id":4094,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:21.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001454771-26-000002","document":"form4-09042026_060910.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454771/000145477126000002/form4-09042026_060910.xml","form_type":"4"}},{"id":1048614,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:22.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023705","document":"form4-09042025_050911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023705/form4-09042025_050911.xml","form_type":"4"}},{"id":1048613,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:22.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing\nupon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023705","document":"form4-09042025_050911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023705/form4-09042025_050911.xml","form_type":"4"}},{"id":1655578,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-07T21:43:19.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-24-000008","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000008/form4.xml","form_type":"4"}},{"id":1655577,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-07T21:43:19.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024."}],"balance_after":65000,"derivative":{"exercise_price":1.11,"expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-24-000008","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000008/form4.xml","form_type":"4"}},{"id":1768755,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-10-03T21:00:58.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013903","document":"form4-10032023_051035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013903/form4-10032023_051035.xml","form_type":"4"}},{"id":2042451,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T21:37:28.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024."}],"balance_after":50000,"derivative":{"exercise_price":1.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001133416-23-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000014/form4.xml","form_type":"4"}},{"id":2162613,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:00:44.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030."}],"balance_after":50000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-098941","document":"tm2225460-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098941/tm2225460-1_4seq1.xml","form_type":"4"}},{"id":2426928,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-25T21:17:48.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023."}],"balance_after":50000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001133416-22-000016","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000016/form4.xml","form_type":"4"}},{"id":2769597,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:34.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results."}],"balance_after":100000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-013816","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013816/doc4.xml","form_type":"4"}},{"id":2769596,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:34.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options vest as follows: 25% on each on September 30, 2021, March 31, 2022, September 30, 2022 and March 31, 2023."}],"balance_after":50000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-21-013816","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013816/doc4.xml","form_type":"4"}},{"id":3209255,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-03-16T20:32:35.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: (i) 20% on each of March 2, 2021, March 2, 2022, March 2, 2023 and (i) 40% on March 2, 2024."}],"balance_after":300000,"derivative":{"exercise_price":1.75,"expiration_date":"2030-03-12","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-20-008455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320008455/doc4.xml","form_type":"4"}},{"id":3305487,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:02:13.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005967","document":"tm205452-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005967/tm205452-2_4.xml","form_type":"4"}},{"id":3681497,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-31T17:28:22.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":138312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on January 1, 2020, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":138312,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":138312},"source":{"system":"sec-edgar","filing":"0001333277-19-000028","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327719000028/edgar.xml","form_type":"4"}},{"id":4088444,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-26T17:08:01.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":125000,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001333277-18-000024","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327718000024/edgar.xml","form_type":"4"}},{"id":4484243,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-23T17:57:36.000Z","date":"2017-01-19","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years."}],"balance_after":100000,"derivative":{"exercise_price":1.72,"expiration_date":"2027-01-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179110-17-001183","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017001183/edgar.xml","form_type":"4"}},{"id":4496708,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-06T19:36:30.000Z","date":"2017-01-04","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On July 25, 2016, the Reporting Person was granted an option to purchase 42,000 shares of common stock of the Issuer.  The option vests in two equal installments based on the Issuer's achieving certain milestones.  The first milestone was met on December 30, 2016, resulting in vesting of the option as to 21,000 shares, which was reported on a prior Form 4.  The second milestone was met on January 4, 2017, resulting in vesting of the option as to the remaining 21,000 shares."}],"balance_after":42000,"derivative":{"exercise_price":1.82,"exercise_date":"2017-01-04","expiration_date":"2026-07-24","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001179110-17-000729","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017000729/edgar.xml","form_type":"4"}},{"id":4503674,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-04T20:09:39.000Z","date":"2016-12-30","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On July 25, 2016, the Reporting Person was granted an option to purchase 42,000 shares of common stock of the Issuer.  The option vests in two equal installments based on the Issuer's achieving certain milestones.  The first milestone was met, resulting in vesting of the option as to 21,000 shares."}],"balance_after":21000,"derivative":{"exercise_price":1.82,"exercise_date":"2016-12-30","expiration_date":"2026-07-24","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001179110-17-000397","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000117911017000397/edgar.xml","form_type":"4"}}]}